Literature DB >> 33142137

Is primary membranous nephropathy a complement mediated disease?

Linda Reinhard1, Rolf A K Stahl2, Elion Hoxha3.   

Abstract

Membranous nephropathy (MN) is an immune complex mediated disease. Although limited to the kidney, in up to 20% of patients MN is associated with other autoimmune, infectious or malignant diseases. The initial pathogenetic event in what is still considered "primary" MN is the binding of circulating autoantibodies to proteins (autoantigens) expressed in glomerular podocytes. This antibody binding leads to the formation of immune complexes in the glomerular basement membrane. There is clinical and experimental evidence that these immune deposits lead to the activation of the complement system. Experimental studies in the MN model of Heymann's nephritis show that the terminal membrane attack complex (MAC) of the complement system induces a disturbance of the glomerular filtration barrier and leads to proteinuria, the clinical hallmark of MN. After the discovery of the phospholipase A2 receptor 1 and thrombospondin type 1 domain containing protein 7A as endogenous antigens, it is assumed that IgG4 antibodies directed against these proteins induce MN in over 85% of patients with primary MN. As a result, the role of complement in the pathogenesis of MN needs to be defined in light of these developments. In this review we describe the current knowledge on the function of the complement system in primary MN and discuss the open questions, which have to be solved for a better understanding of the potential role of complement in the pathophysiology of primary MN.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Complement; IgG4 antibody subclass; Kidney disease; Membranous nephropathy

Year:  2020        PMID: 33142137     DOI: 10.1016/j.molimm.2020.10.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

Review 1.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

2.  Hypercholesterolemia Correlates With Glomerular Phospholipase A2 Receptor Deposit and Serum Anti-Phospholipase A2 Receptor Antibody and Predicts Proteinuria Outcome in Idiopathic Membranous Nephropathy.

Authors:  Lei Dong; Yue-Qiang Li; Shui-Ming Guo; Gang Xu; Wang Wei; Min Han
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

Review 3.  Membranous nephropathy: new pathogenic mechanisms and their clinical implications.

Authors:  Elion Hoxha; Linda Reinhard; Rolf A K Stahl
Journal:  Nat Rev Nephrol       Date:  2022-04-28       Impact factor: 42.439

4.  Retinal drusen in glomerulonephritis with or without immune deposits suggest systemic complement activation in disease pathogenesis.

Authors:  P Harraka; H Mack; D Colville; D Barit; D Langsford; T Pianta; F Ierino; Judy Savige
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

5.  The Association Between Serum Complement 4 and Kidney Disease Progression in Idiopathic Membranous Nephropathy: A Multicenter Retrospective Cohort Study.

Authors:  Jing Liu; Yang Zha; Peng Zhang; Peng He; Lijie He
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

6.  Gene Expression as a Guide to the Development of Novel Therapies in Primary Glomerular Diseases.

Authors:  Panagiotis Garantziotis; Stavros A P Doumas; Ioannis Boletis; Eleni Frangou
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

Review 7.  Mechanisms of Primary Membranous Nephropathy.

Authors:  Yan Gu; Hui Xu; Damu Tang
Journal:  Biomolecules       Date:  2021-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.